

1 August 2013

Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C – 1, Block - G
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

GlaxoSmithKline
Consumer Healthcare Ltd.

DLF Plaza Tower
DLF City Phase-1
Gurgaon 122002
Haryana, India

Tel. (0124) 2540700 / 4057700
Fax. (0124) 2540720-21
www.gsk.com

Dear Sir / Madam,

Subject: Unaudited Financial Results for the Quarter ended 30 June 2013

We would like to inform you that the Board of Directors at a meeting held on Thursday, 1 August 2013 at 12.00 Noon at DLF Plaza Tower, DLF City, Phase - I, Gurgaon 122 002, have, inter alia, considered and taken on record the unaudited financial results for the quarter ended 30 June 2013. We are enclosing a copy of the Unaudited financial results for the quarter ended 30 June 2013 along with the "Limited Review" Certificate, issued by the Auditors for the review done by them, for your records.

We also would like to inform you that Ms. Sonali Khanna has been appointed as the Company Secretary w.e.f. 1 August 2013 in place of Mr. Surinder Kumar, who had decided to step down as the Company Secretary of the Company.

Further Ms. Sonali Khanna shall also act as the Compliance Officer with effect from 1 August 2013.

The above may please be taken as our intimation under Clause 41 and other relevant clauses of the Listing Agreement.

Thanking you.

Yours faithfully,
For GlaxoSmithKline
Consumer Healthcare Limited



Ramakrishnan Subramanian
Director – Finance

PART I							(Rs. in Lakhs)
Statement of Standalone Unaudited Results for the Quarter and six months ended 30/06/2013							
PARTICULARS		3 Months Ended 30/06/2013	Preceding 3 Months Ended 31/03/2013	Corresponding 3 Months Ended 30/06/2012 in the previous year	Year to date figures for current period ended 30/06/2013	Year to date figures for the previous year ended 30/06/2012	Previous year ended 31/12/2012
(Refer Notes Below)		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
Income from Operations							
1	(a) Net Sales / Income from Operations (Net of Excise Duty)	8,52,92	9,39,86	7,29,73	17,92,78	15,42,75	30,79,36
	(b) Other Operating Income	37,38	35,52	28,70	72,90	52,09	1,08,14
	Total Income from operations (Net)	8,90,30	9,75,38	7,58,43	18,65,68	15,94,84	31,87,50
2 Expenses							
	(a) Cost of material consumed	2,81,10	2,78,55	2,57,30	5,59,65	4,79,82	10,19,89
	(b) Purchase of stock-in-Trade	35,70	39,28	30,92	74,98	61,22	1,46,43
	(c) Change of inventories of finished goods, work-in-progress and stock-in-trade	(18,17)	38,09	(17,90)	19,92	59,62	(14,47)
	(d) Employee benefits expense	1,04,41	88,95	79,09	1,93,36	1,45,15	3,01,12
	(e) Advertising & Promotion	1,37,56	1,59,29	1,16,09	2,96,85	2,25,23	4,96,47
	(f) Depreciation and Amortisation expense	12,20	10,70	8,55	22,90	20,47	36,08
	(g) Other Expenses	1,93,66	1,64,92	1,53,55	3,58,58	2,99,36	6,64,65
	Total Expenses	7,46,46	7,79,78	6,27,60	15,26,24	12,90,87	26,50,17
3	Profit from operations before other income, finance costs and exceptional Items (1-2)	1,43,84	1,95,60	1,30,83	3,39,44	3,03,97	5,37,33
4	Other income	38,53	32,44	28,53	70,97	52,99	1,13,79
5	Profit from Ordinary activities before finance costs and exceptional Items (3+4)	1,82,37	2,28,04	1,59,36	4,10,41	3,56,96	6,51,12
6	Finance costs	16	14	83	30	2,01	2,42
7	Profit from ordinary activities after finance costs but before exceptional items (5-6)	1,82,21	2,27,90	1,58,53	4,10,11	3,54,95	6,48,70
8	Exceptional items	-	-	-	-	-	-
9	Profit from ordinary activities before tax (7+8)	1,82,21	2,27,90	1,58,53	4,10,11	3,54,95	6,48,70
10	Tax expense	62,25	71,49	51,93	1,33,74	1,16,38	2,11,93
11	Net Profit from ordinary activities after tax (9-10)	1,19,96	1,56,41	1,06,60	2,76,37	2,38,57	4,36,77
12	Extraordinary items (net of tax expense)	-	-	-	-	-	-
13	Net Profit for the period (11-12)	1,19,96	1,56,41	1,06,60	2,76,37	2,38,57	4,36,77
14	Paid Up equity share capital (Face Value of Equity Shares)	42,06 10	42,06 10	42,06 10	42,06 10	42,06 10	42,06 10
15	Reserve excluding Revaluation Reserve as per Balance Sheet of the previous accounting year						13,18,92
16. i	Earnings per share (before extraordinary items) (of Rs 10/- each) (not annualised):						
	(a) Basic and	28.52	37.19	25.34	65.71	56.72	103.85
	(b) Diluted						
16. ii	Earnings per share (after extraordinary items) (of Rs 10/- each) (not annualised):						
	(a) Basic and	28.52	37.19	25.34	65.71	56.72	103.85
	(b) Diluted						



Part II						
Select Information for the Quarter and six months ended 30/06/2013						
A. PARTICULARS OF SHAREHOLDING	3 Months Ended 30/06/2013	Preceding 3 Months Ended 31/03/2013	Corresponding 3 Months Ended 30/06/2012 in the previous year	Year to date figures for current period ended 30/06/2013	Year to date figures for the previous year ended 30/06/2012	Previous year ended 31/12/2012
1. Public Shareholding						
-Number of Shares	1,15,83,546	1,15,83,546	2,39,03,295	1,15,83,546	2,39,03,295	2,39,03,295
-Percentage of Shareholding	27.54	27.54	56.84	27.54	56.84	56.84
2. Promoters and Promoter Group Shareholding						
a) Pledged/Encumbered						
- Number of shares	-	-	-	-	-	-
- Percentage of shares (as a % of the total shareholding of Promoter and Promoter Group)	-	-	-	-	-	-
- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-	-	-
b) Non-encumbered						
- Number of shares	3,04,71,992	3,04,71,992	1,81,52,243	3,04,71,992	1,81,52,243	1,81,52,243
- Percentage of shares (as a % of the total shareholding of Promoter and Promoter Group)	100.00	100.00	100.00	100.00	100.00	100.00
- Percentage of shares (as a % of the total share capital of the Company)	72.46	72.46	43.16	72.46	43.16	43.16

Particulars	3 months ended 30th Jun 13
B. INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	NIL
Received during the quarter	57
Disposed of during the quarter	57
Remaining unresolved at the end of the quarter	NIL



Standalone Statement of Assets and Liabilities		
Particulars	As at (Current half year end) (30/06/2013) (Rs. in Lakhs)	As at (Previous year end) (31/12/2012) (Rs. in Lakhs)
A. EQUITY AND LIABILITIES		
Shareholders' funds		
a) Share capital	42,06	42,06
b) Reserves and surplus	15,93,84	13,18,92
Sub-total - Shareholders' funds	16,35,90	13,60,98
2. Non-current liabilities		
a) Long term borrowings	-	-
b) Deferred tax liabilities (net)	-	-
c) Other long term liabilities	10,39	11,48
d) Long term provisions	1,12,65	76,80
Sub-total - Non-current liabilities	1,23,04	88,28
3. Current liabilities		
a) Short-term borrowings	-	-
b) Trade payables	5,45,57	4,78,43
c) Other current liabilities	4,68,66	3,51,49
d) Short-term provisions	86,16	2,75,31
Sub-total - Current liabilities	11,00,39	11,05,23
TOTAL - EQUITY AND LIABILITIES	28,59,33	25,54,49
B. ASSETS		
1. Non-current Assets		
a) Fixed assets #	3,81,04	3,91,07
b) Deferred tax assets (net)	69,43	61,63
c) Long-term loans & advances	1,77,58	44,66
d) Other non-current assets	-	-
Sub-total - Non-current assets	6,28,05	4,97,36
2. Current Assets		
a) Inventories	3,58,58	3,69,64
b) Trade receivables	2,62,22	1,12,61
c) Cash and cash equivalents	14,40,15	14,64,24
d) Short term loans and advances	83,76	66,81
e) Other current assets	86,57	43,83
Sub-total - Current assets	22,31,28	20,57,13
TOTAL - ASSETS	28,59,33	25,54,49

Fixed Assets includes CWIP aggregating Rs 32,00.27 Lakhs as at June 30, 2013 (Rs 1,97,23.86 Lakhs as at Dec 31, 2012)



GLAXOSMITHKLINE CONSUMER HEALTHCARE LIMITED
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2013

NOTES

- 1) The Company's nutritional business is India focused and in a single business and geographical segment. Accordingly segment information is not applicable.
- 2) The Company received 57 investor complaints during the quarter ended June 30, 2013 which were duly resolved by the end of the quarter. There were no investor complaints pending at the beginning and at the end of the quarter.
- 3) The unaudited financial results for the quarter ended June 30, 2013 have been reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at its meeting held on August 1, 2013. The Limited Review for the unaudited financial results for the quarter ended June 30, 2013, as required under Clause 41 of the Listing Agreement has been completed by the statutory auditors.
- 4) Figures for the previous period have been regrouped/reclassified wherever necessary, to conform to the current period's classification.

REGD. OFFICE: PATIALA ROAD, NABHA 147201 (PUNJAB).
HEAD OFFICE: DLF PLAZA TOWER, DLF CITY PHASE I,
GURGAON - 122002, HARYANA.

GURGAON
August 1, 2013



ON BEHALF OF THE BOARD

A handwritten signature in blue ink, which appears to be 'Zubair Ahmed', written over a horizontal line.

ZUBAIR AHMED
MANAGING DIRECTOR

The Board of Directors
GlaxoSmithKline Consumer Healthcare Limited
DLF Plaza Tower
DLF City Phase-I
Gurgaon 122002
Haryana, India

1. We have reviewed the results of GlaxoSmithKline Consumer Healthcare Limited (the "Company") for the quarter ended June 30, 2013 which are included in the accompanying "Statement of Standalone Unaudited Results for the Quarter and Six Months ended 30/06/2013" and the statement of assets and liabilities as on that date (the "Statement"), except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the Management but have neither been reviewed nor been audited by us. The Statement has been prepared by the Company pursuant to Clause 41 of the Listing Agreement with the Stock Exchanges in India, which has been initialled by us for identification purposes. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion
4. We have only traced the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' in the Statement from the disclosures made by the Management and are, therefore, not expressing a review opinion thereon.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards notified pursuant to the Companies (Accounting Standards) Rules, 2006 as per Section 211(3C) of the Companies Act, 1956 and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse
Firm Registration Number: 301112E
Chartered Accountants



Usha Rajeev
Partner
Membership Number: 087191

Place: Gurgaon
Date: August 01, 2013